Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 18/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003466 | 0.95 | MCHR1 (0.52) | MCHR1P2RX3KCNH2KDM4C | |
| SCHEMBL5267094 | 0.85 | MCHR1 (0.56) | MCHR1KCNH2 | |
| SCHEMBL4535188 | 0.84 | MCHR1 (0.55) | MCHR1P2RX3KDM4C | |
| SCHEMBL1002918 | 0.84 | MCHR1 (0.55) | MCHR1KCNH2 | |
| SCHEMBL4526497 | 0.81 | MCHR1 (0.57) | MCHR1 | |
| SCHEMBL1002062 | 0.80 | MCHR1 (0.53) | MCHR1KCNH2 | |
| SCHEMBL1002650 | 0.80 | MEN1 (0.45) | MCHR1P2RX3KCNH2KDM4C | |
| SCHEMBL1002361 | 0.79 | MCHR1 (0.54) | MCHR1KCNH2 | |
| SCHEMBL1002649 | 0.79 | MCHR1 (0.62) | MCHR1KCNH2 | |
| SCHEMBL1002625 | 0.78 | MCHR1 (0.56) | MCHR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875633-B2 | 4-[(4-Chlorobenzyl)oxy]-1-(4-[(1E)-3-(methylamino)-1-propen-1-yl]phenyl)pyridin-2(1H)-one; remedy for metabolic disorders such as obesity, diabetes, hormone disorder; cardiovascular disorders (stenocardia, acute or congestive heart failure); nervous system disorders (bulimia, anxiety, epilepsy etc.) | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| EP-1921065-B1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090137587-A1 | Phenylpyridone Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1921065-A1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137587-A1 | Phenylpyridone Derivative | NAT1, NPR1, PC | MCHR1 439/4885P2RX3 2161/4885KCNH2 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.